Literature DB >> 23597560

It's the peptide-MHC affinity, stupid.

Thomas Kammertoens1, Thomas Blankenstein.   

Abstract

Adoptively transferred T cells can reject large established tumors, but recurrence due to escape variants frequently occurs. In this issue of Cancer Cell, Engels et al. demonstrate that the affinity of the target peptide to the MHC molecule determines whether large tumors will relapse following adoptive T cell therapy.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Year:  2013        PMID： 23597560     DOI： 10.1016/j.ccr.2013.04.004

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

Review 1.  A peptide's perspective on antigen presentation to the immune system.

Authors:  Jacques Neefjes; Huib Ovaa
Journal:  Nat Chem Biol       Date:  2013-12       Impact factor: 15.040

2.  Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells.

Authors:  Timothy T Spear; Yuan Wang; Kendra C Foley; David C Murray; Gina M Scurti; Patricia E Simms; Elizabeth Garrett-Mayer; Lance M Hellman; Brian M Baker; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2017-06-20       Impact factor: 6.968

3.  Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice.

Authors:  Matthias Obenaus; Catarina Leitão; Matthias Leisegang; Xiaojing Chen; Ioannis Gavvovidis; Pierre van der Bruggen; Wolfgang Uckert; Dolores J Schendel; Thomas Blankenstein
Journal:  Nat Biotechnol       Date:  2015-03-16       Impact factor: 54.908

Review 4.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

5.  Combining Three-Dimensional Modeling with Artificial Intelligence to Increase Specificity and Precision in Peptide-MHC Binding Predictions.

Authors:  Michelle P Aranha; Yead S M Jewel; Robert A Beckman; Louis M Weiner; Julie C Mitchell; Jerry M Parks; Jeremy C Smith
Journal:  J Immunol       Date:  2020-09-02       Impact factor: 5.422

6.  Codon optimization of the human papillomavirus E7 oncogene induces a CD8+ T cell response to a cryptic epitope not harbored by wild-type E7.

Authors:  Felix K M Lorenz; Susanne Wilde; Katrin Voigt; Elisa Kieback; Barbara Mosetter; Dolores J Schendel; Wolfgang Uckert
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

Review 7.  Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?

Authors:  Thomas C Wirth; Florian Kühnel
Journal:  Front Immunol       Date:  2017-12-19       Impact factor: 7.561

Review 8.  The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses.

Authors:  Diana Campillo-Davo; Donovan Flumens; Eva Lion
Journal:  Cells       Date:  2020-07-18       Impact factor: 6.600

9.  CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity.

Authors:  Petra Baumgaertner; Julien Schmidt; Carla-Marisa Costa-Nunes; Natacha Bordry; Philippe Guillaume; Immanuel Luescher; Daniel E Speiser; Nathalie Rufer; Michael Hebeisen
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

10.  Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.

Authors:  Spencer D Martin; Scott D Brown; Darin A Wick; Julie S Nielsen; David R Kroeger; Kwame Twumasi-Boateng; Robert A Holt; Brad H Nelson
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.